Market Overview

Morgan Stanley Upgrades Gilead Sciences To Overweight, Shares Rise

Related GILD
Technical Alert: Gilead Sciences Makes New For Move
Verastem's CEO Talks DYNAMO Study, The Competitive Landscape And Pitch To Investors
Buy Gilead's HIV Franchise And Get The Rest Of The Company For Free (Seeking Alpha)

Analysts at Morgan Stanley upgraded Gilead Sciences Inc. (NASDAQ: GILD) from undefined to Overweight.

Gilead Sciences shares have jumped 24.92% over the past 52 weeks, while the S&P 500 index has gained 13.45% in the same period.

Gilead Sciences' shares rose 1.92% to $95.59 in pre-market trading.

Latest Ratings for GILD

Nov 2016Stifel NicolausInitiates Coverage OnBuy
Nov 2016MizuhoInitiates Coverage OnBuy
Nov 2016BMO CapitalUpgradesMarket PerformOutperform

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: Morgan StanleyUpgrades Analyst Ratings


Related Articles (GILD)

View Comments and Join the Discussion!